The Journal of Rheumatology最新文献

{"title":"Effects of Juvenile Idiopathic Inflammatory Myopathies on Growth, Development, and Maturation: A Systematic Review and Meta-Analysis.","authors":"Jessica C Guo,Olivia D Garisto,Jessie Cunningham,Y Ingrid Goh,Jill Hamilton,Brian M Feldman","doi":"10.3899/jrheum.2024-0088","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0088","url":null,"abstract":"OBJECTIVEThe purpose of this review is to assess the effects of JIIM on growth and pubertal development.METHODSA systematic review was conducted by searching EMBASE, MEDLINE, PubMed®, PsycINFO, Cochrane, and Web of Science to identify studies published in English from inception to December 2024. Data were extracted regarding puberty- and development-related outcomes. Meta-analyses were conducted for outcomes measured consistently across studies, using the R package metafor (Version 3.4-0).RESULTSOf 5,838 identified unique records, 24 were included. Inter-rater reliability for abstract and full-text screening was Κ=0.93 and Κ=1.0, respectively. Eighteen articles discussed growth (14/18 demonstrated decreased height or growth failure). Meta-analysis of 7 studies noted the overall prevalence of growth failure is 17.9%, 95% C.I. [10.7-25.0]. Five articles reported delays of secondary sex characteristics or puberty. Five articles discussed age of menarche onset; 4 reported delays and one did not.CONCLUSIONJIIM can cause several deleterious effects on development including growth failure. The impact of hormonal changes or delayed puberty has been less well studied. Endocrine abnormalities should be actively screened for and treated. Additional research is needed to assess long-term impacts.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and predictors of achieving sustained remission in psoriatic arthritis. A Swedish nationwide registry study.","authors":"Olafur Palsson,Jon T Einarsson,Johan K Wallman,Thorvardur J Love,Bjorn Gudbjornsson,Meliha C Kapetanovic","doi":"10.3899/jrheum.2024-1250","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1250","url":null,"abstract":"OBJECTIVETo estimate the prevalence and predictors of sustained remission (SR) in psoriatic arthritis (PsA) patients receiving biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in Sweden.METHODSAll PsA patients initiating b/tsDMARDs and who were registered in the national Swedish Rheumatology Quality register (SRQ) April 1999-December 2019 were included. Data on disease/treatment characteristics at first b/tsDMARD (baseline) and all subsequent visits were extracted from SRQ. Remission was defined as DAS28CRP≤2.6, DAPSA28≤4 or the evaluator's global assessment of disease activity (EGA) on a scale 0-4 (remission=0), and SR when these criteria persisted during at least two consecutive visits for ≥6 months. Baseline predictors of SR were explored using logistic regression analysis.RESULTSData on 4.669 PsA patients with 48.773 visits were available. 81% patients achieved DAS28CRP remission ever, and 54% achieved SR at least once. The corresponding percentages for DAPSA28 were 46% and 24%, and for EGA were 69% and 38%, ever reaching remission and SR, respectively. Male sex was positive predictor of reaching SR when measured by DAPSA28 and EGA but not by DAS28CRP. Fewer swollen joints at baseline predicted SR according to all three remission criteria.CONCLUSIONA considerable proportion of PsA patients receiving various b/tsDMARDs never achieved remission, and approximately half never achieved SR in this Swedish nationwide registry study. Fewer swollen joints at first b/tsDMARD start increases the likelihood of SR, regardless of remission criteria used. There was still sex difference when measured with DAPSA28 and EGA, with men being more likely to reach SR.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Early Attainment of Minimal Disease Activity on Radiographic Outcomes: A Real-World Longitudinal Cohort Study in Psoriatic Arthritis.","authors":"Gonul Hazal Koc,Marc R Kok,Selinde V J Snoeck Henkemans,Jolanda J Luime,Ilja Tchetverikov,Jos H van der Kaap,Paul Baudoin,Petra Kok,Yvonne P M Goekoop-Ruiterman,Petra A J M Vos,Maikel van Oosterhout,Lindy A Korswagen,Radboud J E M Dolhain,Marijn Vis","doi":"10.3899/jrheum.2024-1162","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1162","url":null,"abstract":"OBJECTIVETo evaluate the effect of achieving Minimal Disease Activity (MDA) within the first year on radiologic damage at follow-up 3 years in patients with newly diagnosed Psoriatic Arthritis (PsA).METHODSData were used from the Dutch southwest Early PsA cohort, a real-world cohort of newly diagnosed PsA patients, focusing for this manuscript on those with oligoarthritis or polyarthritis. Patients were stratified into three groups: [1] Sustained-MDA- achieving MDA at least at both 9 and 12 months post-diagnosis; [2] Non-sustained-MDA- achieving MDA in the first year but not sustaining it at 9 and 12 months; [3] No-MDA- not achieving MDA in the first year. Radiographic assessment was utilized by the PsA-modified Total Sharp/van de Heijde Score. Group comparisons at follow-up 3 years for radiographic changes were conducted using a Linear Mixed Model.RESULTS284 patients were categorized into three groups: 96 patients (34%) in the sustained- MDA group, 83 (29%) in the non-sustained-MDA group, and 105 (37%) in the no-MDA group. According to baseline characteristics, in the no-MDA group, a notably higher rate of females (70%) and an elevated tender joint count (median (IQR): 7(4-12)) were observed. Patients who did not achieve MDA in the first year experienced remarkably higher radiographic changes during follow-up than the sustained-MDA group (β = 0.05 (95% CI 0.02 to 0.08), p < 0.01).CONCLUSIONRadiographic changes during the 3-year follow-up were markedly higher in those unable to achieve MDA within the first year of follow-up, emphasizing the long-term structural benefits of reaching stringent disease activity targets early in the disease course.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Anti-TNF-α Inhibitors for Refractory Leg Ulcers in Cutaneous Polyarteritis Nodosa: A Case Series.","authors":"Kimie Harama,Takao Sugiyama,Chisaki Ito,Toyohiko Sugimoto,Soichiro Kubota,Ryosuke Ito,Yoshiaki Kobayashi,Shunichiro Hanai,Daiki Nakagomi","doi":"10.3899/jrheum.2025-0140","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0140","url":null,"abstract":"OBJECTIVECutaneous polyarteritis nodosa (cPAN) is a rare necrotizing vasculitis that primarily affects small-to-medium-sized arteries in subcutaneous tissue. cPAN is often characterized by a chronic and relapsing disease that presents with skin ulcers, livedo, and painful erythema. In this study, we evaluated the efficacy of anti-TNF-α inhibitor treatment for cPAN-associated refractory leg ulcers.METHODSThis retrospective study was conducted between 2016 and 2023 at three medical institutions in Japan and targeted patients with cPAN presenting with refractory leg ulcers who were treated with anti-TNF-α inhibitors. The diagnosis of cPAN was histologically confirmed, and patients with secondary PAN were excluded. Data on the clinical background, treatments, ulcer status, and glucocorticoid dosages were collected, and the therapeutic efficacy of the treatment was evaluated.RESULTSTen patients were included, with a mean age of 51 years, and nine were female. All patients presented with recurrent leg ulcers. Anti-TNF-α inhibitors included adalimumab (five cases), etanercept (four cases), and infliximab (one case). Complete epithelialization of the leg ulcers was achieved in all patients, and the average glucocorticoid dose was successfully reduced from 20 mg/day to 3.5 mg/day. Additionally, five patients achieved a glucocorticoid-free status. No serious adverse events were observed in any of the patients.CONCLUSIONAnti-TNF-α inhibitors suggested therapeutic efficacy for cPAN-associated refractory leg ulcers and enabled ulcer epithelialization and significant glucocorticoid dose reduction. These findings support the utility of anti-TNF-α inhibitors in the management of refractory leg ulcers in cPAN, highlighting the need for further large-scale studies to validate the results.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caribbean Crossroads in Rheumatology: Strategies to Establish Our Regional Rheumatic Disease Burden With Lessons and Opportunities for the Global Community.","authors":"Keisha Davis-King,Cindy Flower","doi":"10.3899/jrheum.2024-1214","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1214","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interferon Response Gene Score in Juvenile Dermatomyositis.","authors":"Hanna Kim","doi":"10.3899/jrheum.2025-0395","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0395","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Genetic Analysis of a Female Patient With Adolescent-Onset Gout.","authors":"Xia Li,Meng Zhang,Tong Pan,Jinjing Tian","doi":"10.3899/jrheum.2024-1282","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1282","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"109 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences with Complementary and Integrative Health Among People with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Qualitative Study.","authors":"Sarah L Patterson,Denise Ruvalcaba,Arbella Issa,Krish Rai,Patricia Katz,Christopher J Koenig","doi":"10.3899/jrheum.2024-1218","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1218","url":null,"abstract":"OBJECTIVERheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic immune-mediated inflammatory diseases often complicated by persistent pain and fatigue despite cutting edge pharmacological treatments. Lifestyle medicine (LM) and complementary and integrative health (CIH) offer adjuvant therapies with potential to alleviate these symptoms, but little is known about patients' experiences with these modalities.METHODSThis qualitative study explored the use of LM and CIH among English- and Spanish-speaking patients with RA and SLE. We conducted five focus groups using an original semistructured interview guide to examine participants' experiences with, and barriers to using, LM and CIH. Group discussions were recorded, transcribed verbatim, translated, and analyzed in a multi-step iterative process to identify frequencies and thematic trends.RESULTSThirty-nine participants with RA or SLE discussed using LM and CIH modalities to manage their disease in 130 mentions. Diet was the most frequently discussed lifestyle modality with participants noting specific foods that exacerbated or alleviated symptoms. Traditional Chinese Medicine (TCM) and natural products were the most discussed CIH approaches, and participants expressed a strong interest in exploring additional complementary modalities to mitigate symptoms. The primary barriers to using LM and CIH were uncertainty regarding safe and effective practices and high out-of-pocket expenses.CONCLUSIONPatients with RA and SLE are highly interested in using LM and CIH to manage their conditions, but many are unsure which adjunctive treatment approaches are safe and effective. More research on LM and CIH modalities is needed to facilitate clear, evidence-based answers to these common patient questions.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Calcium Pyrophosphate Crystal Arthritis Induced by Small Molecule Inhibitors in Anticancer Targeted Therapy: A Report of 2 Cases.","authors":"Elia Touma,Amir Bieber,Shay Brikman","doi":"10.3899/jrheum.2025-0027","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0027","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinically Inactive Disease and Remission in Patients with Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post-Hoc Analysis of a Phase III Trial.","authors":"Alessandro Consolaro,Nicolino Ruperto,Daniel J Lovell,Olga Synoverska,Carlos Abud-Mendoza,Alberto Spindler,Yulia Vyzhga,Ekaterina Alexeeva,Jeffrey Chaitow,Peter Chiraseveenuprapund,Irina Lazariciu,Lori Stockert,Mary Jane Cadatal,Annette Diehl,Hermine I Brunner,","doi":"10.3899/jrheum.2024-0536","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0536","url":null,"abstract":"OBJECTIVETo evaluate rates of clinically inactive disease and remission in patients with juvenile idiopathic arthritis (JIA) receiving tofacitinib, using the 2021 Juvenile Arthritis Disease Activity Score (JADAS) thresholds and American College of Rheumatology (ACR) criteria.METHODSThis post hoc analysis included patients with active JIA (polyarticular course JIA, psoriatic arthritis, or enthesitis-related arthritis) enrolled in a phase III, randomized, withdrawal study of tofacitinib. In part 1 (weeks 0-18) patients received open-label tofacitinib. In part 2 (weeks 18-44) patients who achieved ACR improvement ≥30% were randomized to tofacitinib or placebo for 26 weeks/until JIA flare. Disease activity was assessed using the JADAS in 10 joints (JADAS10), based on C-reactive protein, with interpretation as per 2021 polyarthritis thresholds. JADAS10 remission was defined as ≥24 continuous weeks of JADAS10 clinically inactive disease (JADAS10-CID). ACR clinically inactive disease (ACR-CID) and ACR clinical remission were also assessed.RESULTSOf 225 patients with JIA in part 1, 173 (76.9%) were randomized in part 2 to continue tofacitinib or switch to placebo. Rates of JADAS10-CID and ACR-CID increased throughout part 1 to 30.5% and 15.8% (week 18), respectively. In part 2, these were sustained with tofacitinib (week 44: JADAS10-CID: 35.2%; ACR-CID: 25.0%) and decreased when patients switched to placebo (week 44: JADAS10-CID: 25.9%; ACR-CID: 15.3%). A small proportion of patients achieved JADAS10 remission at week 44 (tofacitinib: 14.8%; placebo: 7.1%).CONCLUSIONIn patients with JIA receiving tofacitinib, JADAS10-CID and ACR-CID rates improved rapidly and were sustained over time; a small proportion of patients achieved JADAS10 remission. Inactive disease is a feasible treatment target in patients receiving tofacitinib.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143903052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}